TScan Therapeutics Files 8-K on Exit Activities

Ticker: TCRX · Form: 8-K · Filed: 2025-11-03T00:00:00.000Z

Sentiment: neutral

Topics: corporate-action, filing

TL;DR

TScan 8-K: Exit activities, Reg FD, and financials filed Nov 3, 2025.

AI Summary

TScan Therapeutics, Inc. filed an 8-K on November 3, 2025, reporting on cost associated with exit or disposal activities, Regulation FD disclosure, and other events. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 830 Winter Street, Waltham, Massachusetts.

Why It Matters

This 8-K filing indicates potential restructuring or divestiture activities within TScan Therapeutics, which could impact its future operations and strategic direction.

Risk Assessment

Risk Level: medium — Filings related to exit or disposal activities can signal significant business changes or financial distress, warranting closer investor scrutiny.

Key Players & Entities

FAQ

What specific 'Cost Associated with Exit or Disposal Activities' are detailed in this 8-K filing?

The filing mentions 'Cost Associated with Exit or Disposal Activities' as an item of disclosure but does not provide specific dollar amounts or details within the provided text.

What is the nature of the 'Other Events' reported by TScan Therapeutics?

The provided text for the 8-K filing lists 'Other Events' as a category of disclosure but does not specify what those events are.

When was TScan Therapeutics incorporated and in which state?

TScan Therapeutics, Inc. was incorporated in Delaware.

What is the primary business address for TScan Therapeutics?

The primary business address for TScan Therapeutics is 830 Winter Street, Waltham, Massachusetts 02451.

What is the Commission File Number for TScan Therapeutics?

The Commission File Number for TScan Therapeutics is 001-40603.

From the Filing

0001193125-25-261612.txt : 20251103 0001193125-25-261612.hdr.sgml : 20251103 20251103063534 ACCESSION NUMBER: 0001193125-25-261612 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20251103 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251103 DATE AS OF CHANGE: 20251103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 251442035 BUSINESS ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d873161d8k.htm 8-K 8-K false 0001783328 0001783328 2025-11-03 2025-11-03     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2025     TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-40603   82-5282075 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   830 Winter Street , Waltham , Massachusetts   02451 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code (857) 399-9500 Not Applicable (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trade Symbol(s)   Name of each exchange on which registered Voting Common Stock, $0.0001 par value per share   TCRX   The Nasdaq Global Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 2.05. Costs Associated with Exit or Disposal Activities. On November 3, 2025, TScan Therapeutics, Inc. (the “Company”) initiated a prioritization strategy by which the Company will prioritize the clinical development of its heme program, pause further enrollment in its solid tumor Phase 1 trial, and focus preclinical efforts on in vivo engineering for solid tumors and target discovery in autoimmunity. Pursuant to such strategy, the Company also implemented a workforce reduction of approximately 30% of the Company’s workforce, or 66

View on Read The Filing